Clinical performance and cost analysis of different screening strategies for CIN2+ and CIN3+ diagnoses after 3 years follow-up after adjustment
| Adjusted 1 | Adjusted 2 | |||||||
| Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | |
| ≥CIN2 | ||||||||
| Strategy 1 | 88.7 (80.1 to 97.2) | 86.8 (85.6 to 88.0) | 10.2 (9.0 to 11.4) | 99.8 (99.5 to 99.9) | 96.2 (91.1 to 100) | 86.9 (85.8 to 88.1) | 11.0 (10.0 to 12.1) | 99.9 (99.7 to 99.9) |
| Strategy 2 | 46.2 (32.6 to 59.7) | 90.1 (89.3 to 91.4) | 7.3 (5.5 to 9.7) | 99.0 (98.8 to 99.2) | 50.0 (36.4 to 63.4) | 90.4 (89.4 to 91.5) | 7.9 (6.0 to 10.3) | 99.1 (98.8 to 99.3) |
| Strategy 3 | 92.3 (85.1 to 99.6) | 79.8 (78.4 to 81.2) | 7.0 (6.3 to 7.7) | 99.8 (99.6 to 99.9) | 98.1 (94.3 to 100.0) | 79.9 (78.5 to 81.3) | 7.4 (6.9 to 8.0) | 99.9 (99.7 to 99.9) |
| ≥CIN3 | ||||||||
| Strategy 1 | 93.5 (84.9 to 100.0) | 86.3 (85.1 to 87.5) | 6.3 (5.6 to 7.1) | 99.9 (99.7 to 100.0) | 100.0 (100.0 to 100.0) | 86.4 (85.2 to 87.6) | 6.7 (6.2 to 7.3) | 100.0 (100.0 to 100.0) |
| Strategy 2 | 54.8 (37.3 to 72.4) | 90.2 (89.2 to 91.2) | 5.2 (3.8 to 7.1) | 99.5 (99.3 to 99.7) | 58.1 (40.7 to 75.4) | 90.2 (89.2 to 91.3) | 5.5 (4.1 to 7.4) | 99.5 (99.3 to 99.7) |
| Strategy 3 | 93.5 (84.9 to 100.0) | 79.3 (77.9 to 80.7) | 4.2 (3.8 to 4.7) | 99.9 (99.7 to 100.0) | 100.0 (100.0 to 100.0) | 79.4 (78.0 to 80.8) | 4.5 (4.2 to 4.8) | 100.0 (100.0 to 100.0) |
Adjusted 1: all cases found by other strategies were considered as missed cases. Adjusted 2: all cases found by other strategies were considered as detected cases.
CIN, cervical intraepithelial neoplasia; NPV, negative predictive value; PPV, positive predictive value.